Alnylam Pharmaceuticals Inc. said its non-GAAP net loss for the fourth quarter ended Dec. 31, 2017, was $1.20 per share, compared with the S&P Capital IQ consensus normalized estimate of a per-share loss of $1.36.
The per-share loss widened 11.1% year over year from $1.08.
The aggregate non-GAAP net loss for the period was $115.1 million, compared to a loss of $92.3 million in the year-earlier period.
Net revenues more than doubled year over year to $37.9 million from $17.5 million, results showed.
GAAP net loss totaled $142.2 million, or $1.48 per share, compared with a loss of $112.9 million, or $1.32 per share, in the year-earlier period.
Full-year results
For full-year 2017, the company posted a non-GAAP net loss of $4.40 per share, compared with the S&P Capital IQ consensus normalized estimate of a per-share loss of $5.31.
The company's full-year 2017 per-share loss widened from $3.91 in 2016.
The aggregate non-GAAP net loss for the period was $398.1 million, compared with a loss of $334.6 million in 2016.
Year-to-date net revenues increased 90.7% year over year to $89.9 million from $47.2 million.
The company said GAAP net loss for 2017 totaled $490.9 million, or $5.42 per share, compared with a loss of $410.1 million, or $4.79 per share, in 2016.
